FDA Issues Draft Guidance on Responding to Form 483 Observations

The U.S. Food and Drug Administration (FDA) has published a draft guidance titled "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection". The document provides recommendations for pharmaceutical manufacturers on how to prepare clear, concise, and effective responses to inspection observations listed in an FDA Form 483.

According to the FDA, responses submitted by companies are often "inadequate". Common problems include missing relevant data, submitting excessive or poorly structured information, or failing to properly address the root cause of the observation. Such responses make it difficult for the agency to assess whether deficiencies have been corrected and whether remediation activities are appropriate.

The draft guidance therefore encourages companies to follow a structured and risk-based approach when responding to inspection findings. Firms should evaluate the significance of the observation, identify the underlying root cause, assess potential risks to patients, and implement appropriate corrective and preventive actions.

In addition, the guidance provides recommendations on how to handle scientific or technical disagreements with FDA observations.

The draft guidance reflects the FDA's current thinking on how manufacturers should respond to Form 483 observations but is not legally binding. Stakeholders may submit comments on the draft guidance by May 8, 2026.